Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: An exploratory analysis of initial AFA dosage in Gio-Tag Japan, a multicenter prospective observational study

被引：0
|
作者：
Hata, A. [1 ]
Takase, N. [2 ]
Sumi, T. [3 ]
Yoshioka, H. [4 ]
Fujisaka, Y. [5 ]
Ota, T. [6 ]
Osugi, J. [7 ]
Mitsui, M. [8 ]
Morita, R. [9 ]
Morita, S. [10 ,11 ]
Sakai, K. [12 ]
Nishio, K. [13 ]
Katakami, N. [14 ]
机构：
[1] Kobe Minimally Invas Canc Ctr, Div Thorac Oncol, Kobe, Hyogo, Japan
[2] Takarazuka City Hosp, Dept Resp Med, Takarazuka, Hyogo, Japan
[3] Hakodate Goryoukaku Hosp, Dept Resp Med, Hakodate, Hokkaido, Japan
[4] Kansai Med Univ, Thorac Oncol Dept, Hirakata, Osaka, Japan
[5] Osaka Med & Pharmaceut Univ Hosp, Clin Res Ctr, Dept Resp Med & Thorac Oncol, Takatsuki, Osaka, Japan
[6] Kyoto City Hosp, Dept Resp Med, Kyoto, Japan
[7] Southern Tohoku Hosp, Dept Thorac Surg, Fukushima, Japan
[8] Hachinohe Municipal Hosp, Dept Thorac Surg, Hachinohe, Aomori, Japan
[9] Akita Kousei Med Ctr, Dept Resp Med, Akita, Japan
[10] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[11] Kyoto Univ, Fac Med, Kyoto, Japan
[12] Kindai Univ, Fac Med, Dept Genome Biol, Osaka, Japan
[13] Kindai Univ, Sch Med Main Campus, Dept Genome Biol, Osaka, Japan
[14] Takarazuka City Hosp, Med Oncoloty Dept, Takarazuka, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
680P
引用
收藏
页码：S1659 / S1659
页数：1
相关论文
共 12 条
  • [1] Sequential afatinib (AFA) to osimertinib (OSI) in EGFRmutant NSCLC: An exploratory analysis of initial AFA dosage in Gio-Tag Japan, a multicenter prospective observational study
    Hata, A.
    Takase, N.
    Sumi, T.
    Yoshioka, H.
    Fujisaka, Y.
    Ota, T.
    Osugi, J.
    Mitsui, M.
    Morita, R.
    Morita, S.
    Sakai, K.
    Nishio, K.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2024, 35
  • [2] Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: Primary analysis of Gio-Tag Japan, a multicenter prospective observational study
    Takase, N.
    Hata, A.
    Sumi, T.
    Yoshioka, H.
    Fujisaka, Y.
    Ota, T.
    Osugi, J.
    Mitsui, M.
    Morita, R.
    Morita, S.
    Sakai, K.
    Nishio, K.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S811 - S811
  • [3] Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report
    Morita, R.
    Hata, A.
    Ota, T.
    Sumi, T.
    Yoshioka, H.
    Osugi, J.
    Fujisaka, Y.
    Mitsui, M.
    Morita, S.
    Katakami, N.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S466 - S467
  • [4] Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
    Hata, Akito
    Katakami, Nobuyuki
    Takase, Naoto
    Kibata, Kayoko
    Yamanaka, Yuta
    Tamiya, Motohiro
    Mori, Masahide
    Kijima, Takashi
    Morita, Satoshi
    Sakai, Kazuko
    Nishio, Kazuto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study)
    Hata, A.
    Katakami, N.
    Nishino, K.
    Mori, M.
    Yokoyama, T.
    Kurata, T.
    Tachihara, M.
    Takase, N.
    Daga, H.
    Kijima, T.
    Morita, S.
    Sakai, K.
    Nishio, K.
    Satouchi, M.
    Negoro, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
    Gwo-Fuang Ho
    Chee-Shee Chai
    Adlinda Alip
    Mohd Ibrahim A. Wahid
    Matin Mellor Abdullah
    Yoke-Ching Foo
    Soon-Hin How
    Adel Zaatar
    Kai-Seng Lam
    Kin-Wah Leong
    John-Seng-Hooi Low
    Mastura Md Yusof
    Erica Chai-Yong Lee
    Yok-Yong Toh
    Chong-Kin Liam
    BMC Cancer, 19
  • [7] Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
    Ho, Gwo-Fuang
    Chai, Chee-Shee
    Alip, Adlinda
    Wahid, Mohd Ibrahim A.
    Abdullah, Matin Mellor
    Foo, Yoke-Ching
    How, Soon-Hin
    Zaatar, Adel
    Lam, Kai-Seng
    Leong, Kin-Wah
    Low, John-Seng-Hooi
    Yusof, Mastura Md
    Lee, Erica Chai-Yong
    Toh, Yok-Yong
    Liam, Chong-Kin
    BMC CANCER, 2019, 19 (01)
  • [8] A prospective observational multicenter study on osimertinib resistance using ctDNA analysis in EGFR-mutated NSCLC
    Osuga, Mitsuo
    Tamiya, Akihiro
    Harada, Daijiro
    Mizumori, Yasuyuki
    Isa, Shunichi
    Taniguchi, Yoshihiko
    Nakamura, Keiichi
    Shinohara, Tsutomu
    Yanai, Hidetoshi
    Nakatomi, Katsumi
    Oki, Masahide
    Mori, Masahide
    Kuwako, Tomohito
    Yamazaki, Koji
    Ando, Masahiko
    Koh, Yasuhiro
    CANCER SCIENCE, 2025, 116 : 330 - 330
  • [9] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)
    Popat, S.
    Jung, H. A.
    Lee, S. Yup
    Hochmair, M. J.
    Lee, S. H.
    Escriu, C.
    Lee, M. K.
    Migliorino, M. R.
    Lee, Y. C.
    Girard, N.
    Daoud, H.
    Maerten, A.
    Miura, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S971 - S972
  • [10] Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study)
    Tamiya, M.
    Hata, A.
    Katakami, N.
    Kaji, R.
    Yokoyama, T.
    Toshihiko, K.
    Inoue, T.
    Kimura, H.
    Yano, Y.
    Tamuta, D.
    Morita, S.
    Negoro, S.
    ANNALS OF ONCOLOGY, 2017, 28
12